Article

PDT laser receives expedited review status

The FDA has accepted for filing and granted expedited review status to the Miravant Medical Technologies' premarket application for the IRIS Medical OcuLight 664 ophthalmic photodynamic therapy (PDT) laser used to activate drug SnET2, a proposed drug and light treatment for patients with wet age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
(Image credit: AdobeStock/Justlight)
June 18th 2025

Ruth Hogg, PhD, on what retinal imaging can tell clinicians about the brain and body

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Ocular Therapeutix to present at Clinical Trials at the Summit 2025
June 18th 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy
June 18th 2025

Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy

Pathways for better care: When patients and providers move in sync
June 18th 2025

Pathways for better care: When patients and providers move in sync

© 2025 MJH Life Sciences

All rights reserved.